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S296 Poster Session IIhomozygotes. The DFS of one year was 72.2% when the donors
have three or more aKIR, while if the donor had one or two
aKIR., the DFS of one year was 81.8%.
Conclusions: In HLA-identical sibling HSCT, the incidence of
aGVHD and severe aGVHD were higher in group of donor/recipi-
ent KIR completely identical.The differential expression of the num-
ber and subtype in aKIR may be related to the reduce occurrence of
disease relapse and better clinical outcome in HLA-identical sibling
HSCT.393
DAY +11 METHOTREXATE (MTX) MIGHT REDUCE THE RISK OF EN-
GRAFTMENT SYNDROME (ES) AND ACUTE GRAFT-VERSUS-HOST DIS-
EASE (GVHD) AFTER UNRELATED BONE MARROW TRANSPLANTATION
(U-BMT) WITH REDUCED-INTENSITY CONDITIONING REGIMENS
Yakushijin, K.1,2, Asakura, Y.1, Maeda, T.1, Kurosawa, S.1,
Hiramoto, N.1, Kim, S.-W.1, Mori, S.-I.1, Tanosaki, R.1, Heike, Y.1,
Takaue, Y.1, Tobinai, K.1, Fukuda, T.1 1National Cancer Center Hospi-
tal, Tokyo, Japan; 2Kobe University Hospital, Kobe, Japan
The combination of calcineurin inhibitor and short MTX is often
used for GVHD prophylaxis after allogeneic stem cell transplanta-
tion. Although day +11 MTX is sometimes omitted due to severe
complications, the benefit of day +11MTX is controversial. To eval-
uate the role of day +11 MTX, we retrospectively reviewed the med-
ical records of 142 pts with various hematological malignancies who
underwent U-BMT between 2000 and 2007 with myeloablative
(MAC, n 5 96) or reduced-intensity conditioning (RIC, n 5 46)
regimens. Patient characteristics are shown in table 1.
Table 1. Patient Characteristics
Myeloablative Reduced-intensityDose of
MTX(MAC, n596) (RIC, n546)3 doses
(n514)4 doses
(n582)3 doses
(n512)4 doses
(n534)Age median
(range)34 (22-48) 39 (9-58) 57 (19-67) 56 (10-64)Disease AML 9 32 7 13
ALL 0 12 0 1
MDS 0 14 1 7
CML 1 11 0 2
ML 1 9 3 7
other 3 4 1 4Risk group High risk 11 57 10 22
Low risk 3 25 2 12HLA status identical 12 75 12 34
mismatched 2 7 0 0Calcineurin
inhibitorCyclosporine 5 38 7 24Tacrolimus 9 44 5 10MAC consisted of 12 Gy TBI-based (n5 50) or Bu (po 16 mg/kg or
iv 12.8 mg/kg, n5 46)-based regimen, and RIC consisted of Bu (po 8
mg/kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg) or Flu (180 mg/m2). GVHD prophylaxis consisted of cyclospor-
ine (starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml) or tacrolimus (starting dose 0.03 mg/kg/day civ, target whole
blood conc. 10-20 ng/ml) with short MTX scheduled on day +1, +3,
+6, and day +11 (10-7-7-7 mg/m2). No pts received ATG. Among
the 142 pts, planned day +11 MTX was omitted in 26 pts (MAC; n
5 14, RIC n5 12) due to various reasons including grade 3mucositis
(n5 21), febrile neutropenia (n5 12), grade 2 jaundice (n5 4), grade
2 mucositis (n 5 3), pneumonia (n 5 1), and sepsis (n 5 1). ES was
diagnosed when pts presented with $ 2 of the following symptoms
within 96 hrs of neutrophil engraftment: (1) fever (. 38C) without
an identifiable infectious reason, (2) skin rash (. 25% of BSA) not
because of drug reactions, (3) weight gain (. 2.5% of baseline
body weight), and (4) hypoxia (SPO2\ 94%), or pulmonary infil-
trates. The median follow-up in surviving pts was 1115 days (100-
3071). In both MAC and RIC groups, median day of neutrophilengraftment, OS, NRM and relapse rate at 2 yrs were not signifi-
cantly different between the 4-dose and 3-dose groups (MAC; day
+17 vs +16, 59% vs 48%, 23% vs 25%, and 26% vs 34%, RIC; day
+18.5 vs +16.5, 45% vs 58%, 43% vs 28%, and 20% vs 19%, respec-
tively). In the MAC group, there were no significant differences of
the incidences of ES and grade II to IV acute GVHD. In the RIC
group, however, the incidence of ES was significantly lower in the
4-dose group (26% vs 58%, p 5 0.02) and the incidence of grade
II to IV acute GVHD tended to be lower (48% vs 75%, p 5 0.07)
than in the 3-dose group. In conclusion, our study suggested that
day +11 MTX might reduce the risk of ES and acute GVHD.394
EVALUATION OF MYOCARDIAL AND HEPATIC T2* MRI CHANGES IN b-
THALASSEMIA MAJOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
RECIPIENTS AND THE EFFECT OF IRON OVERLOAD THERAPY
Hamidieh, A.A., Moeininia, F., Alimoghaddam, K., Jalili, M.,
Shamshiri, A., Ghavamzadeh, A. Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
Background: Iron deposition in the heart and liver are considered to
play a central role in the long term outcome of ex-thalassemic hem-
atopoetic stem cell transplantation (HSCT) survivors. There is a lack
of correlation between heart and liver iron load. Serum ferritin and
liver iron values have almost no predictive value for cardiac iron de-
position. This study was conducted in order to assess myocardial and
hepatic iron concentrations using T2* MRI and detection of any ef-
fect of transplantation itself and chelation therapy in ex-thalassemic
patients who survived beyond six months.
Methods: In this prospective, single-center study, during 14
months, 72 major thalassemia patients candidate for allogeneic
HSCTwere evaluated for iron overload by base line liver and cardiac
T2* MRI, liver biopsy and serum ferritin and subsequently 26 pa-
tients assessed again by T2*MRI and ferritin on 6th months after
successful HSCT. Finally deferoxamine was prescribed for 12 ex-
thalassemic patients at this time according to abnormal myocardial
or hepatic T2* values. T2* MRI and serum ferritin were performed
for these patients at the end of 6th months of chelation.
Results: At baseline, the cardiac T2* was normal (. 20 ms) in 46
(63.9%) of recipients, but 69 (82%) had hepatic siderosis. The liver
T2* (mean, 4.27 6 4.22 ms) was correlated significantly with serum
ferritin levels (r-0.8, p \ 0.001), but not with myocardial values
(mean, 25.3 6 10.5 ms). Although serum ferritin increased during
six months after HSCT (mean13516 941 to 5068 6 7674 ng/ml),
the myocardial and hepatic T2* measures were not changed signifi-
cantly. After about 6 months chelation therapy in 12 ex-thalassemic
patients the liver T2* improved (5.49 6 2.74 to 4.216 2.6 ms,
p0.008) with concomitant improvement in serum ferritin (mean
50686 7674 to 24506 1824 ng/ml), but differences in ferritin levels
were not significant. The cardiac T2* measures were not improved
during this time.
Conclusion: T2*MRI is an apropriate method for baseline evalua-
tion and monitoring of chelation therapy in b-thalassemia major
HSCT recipients, where as serum ferritin level may be confusing.395
IMPORTANCE OF CYCLOSPORINE LEVELS IN THE EARLY PERIOD AFTER
REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANS-
PLANTATION
Garcıa, I.C.1, Valcarcel, D.F.2, Pi~nana, J.L.R.1, Martino, R.B.1,
Barba, P.S.2, Novelli, S.C.1, Sureda, A.B.1, Briones, J.M.1,
Delgado, J.G.1, Brunet, S.M.1, Sierra, J.G.1, Sierra, G.J.1 1Hospital de
la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain; 2Hospital Vall
d’ Hebron, Barcelona, Barcelona, Spain
Background: The importance of cyclosporine (CsA) levels to pre-
vent acute graft versus host disease (aGVHD) has been well docu-
mented after conventional conditioning allogeneic stem cell
transplatation (Allo-SCT), but its value in the reduced intensity con-
ditioning (RIC) setting has not been evaluated. The aim of the study
Poster Session II S297was to analyze the impact of CsA levels in the development of grade
2-4 aGVHD in the setting of allo-RIC in the first four weeks after
transplantation.
Patients and Methods: We included 156 consecutive patients [64
(41%) women], median age 52 (17-69) years, who underwent
HLA-identical sibling allo-RIC at a single institution. RIC included
fludarabine 150 mg/m2 plus busulfan 10 mg/kg (for myeloid malig-
nancies n 5 53) or melphalan 70-140 mg/m2 (lymphoid malignan-
cies n 5 103). GVHD prophylaxis was based on CsA plus
methotrexate (MTX) (n 5 121, 78%) or mychopenolate mofetil
(MMF) (n 5 35, 22%). CsA levels were measured at least twice
weekly during the first four weeks (or until discharge) and the dose
was adjusted to maintain blood levels between 200 and 300 ng/ml.
Results:As the use ofMTXvsMMFdid not impact on the incidence
of grades 2-4 aGVHD patients were analyzed together. The median
blood concentrations of CsA at 1st, 2nd, 3rd and 4th weeks after allo-
SCT were 134 (95 CI:10-183), 219 (95 CI: 54-261), 253 (95 CI: 53-
314) and 224 ng/ml (95 CI:30-411) respectively. The number of pa-
tients who were in the optimal range in the 1st, 2nd, 3rd and 4th
weeks after allo-RIC were 34/150 (22%), 92/154 (59%), 86/148
(58%) and 53/123 (56%). Sixty six patients developed grade 2-4
aGVHD for a cumulative incidence of 42% (95% CI 35-51%) at
a median of 38 (range:18-138) days after allo-SCT. In univariate
analysis the variables associated with a higher incidence of 2-4
aGVHDwere: male sex (p5 0.016), female to male donor-recipient
sex combination (p 5 0.05), and median CsA levels in the second (p
5 0.02) and third (p5 0.02) weeks. In multivariate analysis, the only
significant variables associated with higher 2-4 aGVHDwere female
to male donor-recipient sex combination (HR 2; p 5 0.01) and the
median CsA levels in the third week (HR 0.097, p 5 0.039).
Conclusion:The levels of CsA in the immediate post-transplant pe-
riod were suboptimal in almost 50% of patients. Low levels of CsA
were associated with higher incidence of grade 2-4 aGVHD. A
more stringent monitoring and modification of CsA in the early
phase post-Allo-RIC may be helpful to prevent aGVHD.396
ANALYSIS OF THE FLT3-ITD AND NPM1 MUTATIONS IN AML PATIENTS
WITH INTERMEDIATE RISK RECEIVING ALLOGENEIC STEM-CELL TRANS-
PLANTATION
Ogasawara, M., Yamakawa, T., Katsura, Y., Shima, K., Matsukawa, T.,
Kanaya, M., Minauchi, K., Nakata, M., Ota, S., Imai, K., Hirano, T.,
Kobayashi, N., Kiyama, Y. Sapporo Hokuyu Hospital, Sapporo, Japan
Background: Chromosomal abnormality is the most important
prognostic factor for AML patients. Recently, prognosis of cytoge-
netically normal AML patients has been reported to be affected by
the presence of fms-like tyrosine kinase 3 gene internal tandem
duplication (FLT3-ITD) and nucleophosmin 1 gene (NPM1)
mutations. In the present study, we analyzed retrospectively the
FLT3-ITD and NPM1 mutations in AML patients with cytogenet-
ically intermediate risk who received allo-SCT and we evaluated the
effect of the mutations on the outcome of allo-SCT.
Patients and Methods: 23 patients (11 males and 12 females) with
a median age of 46 years (range: 27-65) receiving allo-SCT between
2005 and 2009 whose BM samples were available were enrolled in
this study. Allo-SCT consisted of 10 matched siblings, 8 matched
unrelated donors and 5 unrelated cord blood. GVHD prophylaxis
included CsA/ short term MTX (10) or FK/short term MTX (13).
GenomicDNAwas extracted fromPBMCand amplified by PCRus-
ing specific primers. Analysis of FLT3-ITD or NPM1 exon 12 mu-
tations was carried out by either electrophoresis or direct DNA
sequencing.
Results: FLT3-ITD mutation was found in 5 patients (21.7%).
FLT3-ITD mutation occurred only in cytogenetically normal pa-
tients (positivity: 38.5%). On the other hand, NPM1 mutation was
found in 6 patients (26.1%). Acute GVHD above grade II was found
in 4 patients (57.1%)with FLT3-ITDmutationwhile only 3 patients
(20.0%) without FLT3-ITDmutation manifested the complication.
Frequency of acute GVHD above grade II was 33% and 41% in
NPM1 mutation positive and negative patients, respectively. All
the patients with FLT3-ITDmutation manifested relapse of the dis-
ease following allo-SCTwhile relapse occurred in 5 patients (33.3%)without FLT3-ITD mutation. However, there was no marked dif-
ference in relapse rate between patients with or without NPM1 mu-
tation (33% vs. 41%). Median period of overall survival was 0.184
and 1.619 years in FLT3-ITD mutation positive and negative pa-
tients, respectively.
Conclusions: It was demonstrated that the rate of both relapse and
acute GVHD was significantly higher in AML patients with FLT3-
ITD mutation compared to FLT3-ITDmutation negative patients.
NPM1 mutation exerted minimal effect on the incidence of acute
GVHD and relapse of the disease. These results suggested that
allo-SCT patients with cytogenetically intermediate risk can be
stratified to poor prognosis group if FLT3-ITD mutation is
identified.397
PLASMA CYTOKINE PROFILES AT DAY ZERO: MYELOABLATIVE CONDI-
TIONING EXHIBITS A MORE INFLAMMATORY PROFILE THEN REDUCED
INTENSITY CONDITIONING IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Grimley, M.1, Rehman, N.1, Mellor Heinke, S.1, Villanueva, J.1,
Marsh, R.1, Bleesing, J.1, Mehta, P.1, Jordan, M.1, Kim, M.-O.2,
Li, D.2, Davies, S.1, Filopovich, A.1 1Cincinnatio Children’s Hospital
Medical Center, Cincinnati, OH; 2Cincinnati Children’s HospitalMedical
Center, Cincinnati, OH
While myeloablative conditioning (MAC) has been the conven-
tional preparative regimen for allogeneic stem cell transplant, re-
duced intensity conditioning (RIC) has increasingly been used,
especially in non-malignant conditions. MAC has been associated
with a cytokine storm that may contribute to graft versus host disease
(GVHD) while RIC has shown lower tissue damage which may lead
to a lower release of inflammatory cytokines. We hypothesized that
patients receiving MAC would express a more inflammatory subset
of plasma cytokines on Day Zero compared to patients receiving
RIC.
METHODS:Weprospectively collected samples on 52 consecutive
consented patients who underwent allogeneic transplantation at
Cincinnati Children’s Hospital Medical Center between December
2007 and October 2008. Blood samples were collected at Day 0.
Patient Characteristics are in Table 1.
Table 1.
RIC MACNumber of Patients 23 29
Patient Age -median
(range) years
6.7 (0.6-17.9) 8.1 (0.8-19.4)Patient Gender 13 males/10 females 20 males/9 females
Diagnosis 23 non-malignant 12 malignant/17
non-malignantABio-Plex Pro Assay was used tomeasure plasma levels of GM-CSF,
G-CSF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
13, IL-17, IFN-g, MCP-1, MIP-1b, TNF-a, IL-18, and MIF.
Plasma concentrations of sTNF-R1 were measured by ELISA. Sol-
uble IL-2 Receptor alpha (sIL2Ra) levels were measured using the
Immulite platform.
RESULTS: Wilcoxon rank sum test was used to compare the
plasma cytokine levels between the RIC and MAC groups. IL-6,
G-CSF, sIL-2Ra, IL-17 and IL-7 plasma levels were found to be dif-
ferent in the two groups (p # 0.05). We additionally analyzed 2
groups within the RIC cohort-10 patients received distal alemtuzu-
mab (between Days -22 and -13 pretransplant) and 12 patients re-
ceived proximal alemtuzumab (between Days -12 and -8
pretransplant). In this analysis, patients who received distal alemtu-
zumab have higher levels of the tested cytokines including IL-1b,
IL-6, IL-8, IFN-g, MIF and TNF-a (p # 0.05).
DISCUSSION:A pro-inflammatory cytokine profile (increased IL-
6, G-CSF and sIL-2Ra) is seen in MAC patients when compared to
RIC patients who have increased levels of differentiation (IL-17) and
growth (IL-7) cytokines. The timing of alemtuzumab prior to trans-
plant affects the cytokine profile on Day 0. Patients receiving distal
alemtuzumab have higher levels of the pro-inflammatory cytokines
